**South Africa**

**Population 2017**

57 million

---

### Tuberculosis Profile

#### Population 2017

- **57 million**

#### Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>22 (20–24)</td>
<td>39 (35–43)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>56 (39–77)</td>
<td>99 (68–135)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>322 (230–428)</td>
<td>567 (406–754)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>193 (137–258)</td>
<td>340 (241–455)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>12 (7.7–17)</td>
<td>21 (14–30)</td>
</tr>
</tbody>
</table>

#### Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>18 (9.5–27)</td>
<td>20 (11–30)</td>
<td>39 (25–52)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>116 (60–172)</td>
<td>167 (87–247)</td>
<td>283 (185–381)</td>
</tr>
<tr>
<td>Total</td>
<td>135 (77–192)</td>
<td>187 (107–267)</td>
<td>322 (230–428)</td>
</tr>
</tbody>
</table>

#### TB case notifications, 2017

- **Total cases notified**: 250,354
- **Total new and relapse**: 243,297
- **% tested with rapid diagnostics at time of diagnosis**: 60%
- **% with known HIV status**: 94%
- **% pulmonary**: 89%
- **% bacteriologically confirmed among pulmonary**: 67%

#### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2017**: 76% (57–110)
- **TB patients facing catastrophic total costs**: 0.25 (0.16–0.35)

#### Treatment success rate and cohort size

- **New and relapse cases registered in 2016**: 82% | 236,702
- **Previously treated cases, excluding relapse, registered in 2016**: 62% | 5,129
- **HIV-positive TB cases registered in 2016**: 80% | 133,710
- **MDR/RR-TB cases started on second-line treatment in 2015**: 55% | 9,750
- **XDR-TB cases started on second-line treatment in 2015**: 48% | 427

#### TB preventive treatment, 2017

- **% of HIV-positive people (newly enrolled in care) on preventive treatment**: 53%
- **% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment**: 68% (63–75)

#### TB financing, 2018

- **National TB budget (US$ millions)**: 271

- **Funding source**: 91% domestic, 8% international, <1% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed